ObjectivesCombining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in hepatitis C virus (HCV)-infected patients, but this strategy remains to be validated in HIV/HCV coinfection. We compared the performances of transient elastography (TE), Fibrotest (FT), the aspartate aminotransferase-to-platelet ratio index (APRI) and two algorithms combining TE and FT (Castera) or APRI and FT (SAFE) in HIV/HCV coinfection.
MethodsOne hundred and sixteen HIV/HCV-coinfected patients (64% male; median age 44 years) enrolled in two French multicentre studies (the HEPAVIH cohort and FIBROSTIC) for whom TE, FT and APRI data were available were included in the study. Diagnostic accuracies for significant fibrosis (METAVIR F ≥ 2) and cirrhosis (F4) were evaluated by measuring the area under the receiver-operating characteristic curve (AUROC) and calculating percentages of correctly classified (CC) patients, taking liver biopsy as a reference.
ResultsFor F ≥ 2, both TE and FT (AUROC = 0.87 and 0.85, respectively) had a better diagnostic performance than APRI (AUROC = 0.71; P < 0.005). Although the percentage of CC patients was significantly higher with Castera's algorithm than with SAFE (61.2% vs. 31.9%, respectively; P < 0.0001), this percentage was lower than that for TE (80.2%; P < 0.0001) or FT (73.3%; P < 0.0001) taken separately. For F4, TE (AUROC = 0.92) had a better performance than FT (AUROC = 0.78; P = 0.005) or APRI (AUROC = 0.73; P = 0.025). Although the percentage of CC patients was significantly higher with the SAFE algorithm than with Castera's (76.7% vs. 68.1%, respectively; P < 0.050), it was still lower than that for TE (85.3%; P < 0.033).
ConclusionsIn HIV/HCV-coinfected patients, TE and FT have a similar diagnostic accuracy for significant fibrosis, whereas for cirrhosis TE has the best accuracy. The use of the SAFE and Castera algorithms does not seem to improve diagnostic performance. On average, nearly half of patients have developed liver cirrhosis after 25 years of HCV infection. Assessment of liver fibrosis is thus of critical importance in HIV/HCV-coinfected patients not only for prognosis but also for antiviral therapy indications. Indeed, two endpoints are clinically relevant: (i) the presence of significant fibrosis, which is the hallmark of progressive disease and an indication for antiviral treatment; (ii) the presence of cirrhosis, which is an indication for specific monitoring of complications related to portal hypertension and to the increased risk of developing hepatocellular carcinoma [4]. Liver biopsy (LB) is classically considered the gold standard for staging fibrosis [5], although it has several limitations: it is an invasive and painful procedure [6][7][8], with rare but potentially life-threatening complications [9], and prone to sampling errors [10][11][12]. Thus, many patients are reluctant to undergo LB, especially HIV/HCV-coinfected patients who may be discouraged from initiating anti-HCV treatment for this reason.These limitations have stimulated the search fo...